No alteration of fertility was detected. Caution should be exercised when prescribing Aranesp to pregnant women. This section contains information on how to
Please see ARANESP full Prescribing Information, including Boxed WARNINGS and Medication Guide. Please see EPOGEN full Prescribing Information, including
Under the REMS program, referred to as the ESA APPRISE Oncology Program, healthcare providers that prescribed and/or dispensed Aranesp to patients with cancer and hospitals that dispensed Aranesp
See full prescribing information for complete boxed warning. Renal Insufficiency (CHOIR) and Trial to Reduce Cardiovascular Events with Aranesp Therapy.
A special MedGuide will be given to you by the pharmacist with each prescription and refill. Additional Information From Chemocare.com About Aranesp.
Do not shake Aranesp. Shaking could cause Aranesp not to work. If you shake Aranesp the solution may look foamy and it should not be used. Do not freeze Aranesp. Do not use an Aranesp prefilled syringe that has been frozen. Keep Aranesp away from light. How should I prepare for an injection of Aranesp?
ARANESP every 2 ( -Single 500 Single 300 -HIGHLIGHTS OF PRESCRIBING INFORMATION These hig hlights do not include all the informatio n nee ded to use safely and effectively. See full prescr ibing information for ARANESP. ARANESP (darbepoetin alfa) injection, for intravenous or subc utaneous use Initial U.S. Approval: 2024
EU Commission Approves Updated Prescribing Information for Aranesp(R) THOUSAND OAKS, Calif.-(BUSINESS WIRE)-Ma-Amgen (NASDAQ: AMGN) today announced that the European Commission reached its final decision to amend the prescribing information for Aranesp(R) (darbepoetin alfa) based on the positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) in
with Aranesp (5.4). Seizures: Aranesp increases the risk for seizures in patients with CKD (5.5). Increase monitoring of these patients for changes in seizure frequency or premonitory symptoms (5.5). PRCA: If severe anemia and low reticulocyte count develop during Aranesp treatment, withhold Aranesp and evaluate for PRCA (5.7).
Comments